FY23 DoD Melanoma Idea Award | HT9425 23 MRP IA

Opportunity Information: Apply for HT9425 23 MRP IA

The FY23 DoD Melanoma Research Program (MRP) Idea Award is a funding opportunity from the Department of Defense (administered by the U.S. Army Medical Research Acquisition Activity, USAMRAA) designed to jump-start brand-new directions in melanoma research. It specifically targets projects that are innovative, untested, and exploratory, with an emphasis on high-risk ideas that could deliver high-impact payoffs if they work. To be responsive, proposals must address at least one of the FY23 MRP Focus Areas referenced in the announcement (listed in the full solicitation under Section II.A.1), meaning applicants need to clearly connect their concept to those program priorities rather than proposing melanoma research in a general or loosely related way.

At the core of this award is the expectation of genuine novelty. The program is looking for concepts that introduce a new paradigm, challenge existing assumptions, or tackle established problems from a fresh angle. That could mean proposing an unconventional mechanism, a creative model system, a new analytical method, or an original conceptual framework that changes how melanoma is studied or understood. The research can be hypothesis-driven, hypothesis-generating, or broadly exploratory, but it still needs to be grounded in a credible scientific rationale and laid out with a rigorous study design, including a clear plan for how data will be analyzed. In other words, the idea can be bold and uncertain, but the approach has to be thoughtfully constructed and technically sound.

Equally important is what the award does not want to fund. The Idea Award is not meant to extend an applicant's existing body of work, continue an established line of investigation already underway in their lab, or produce incremental advances that represent the next expected step. Simply applying an existing approach to melanoma because it worked in another cancer, or swapping in a different tumor type without a truly new conceptual leap, is specifically framed as insufficiently innovative for this mechanism. The aim is to open up new research avenues rather than to scale, optimize, or slightly modify work that is already well supported or well developed.

A defining feature of the opportunity is its stance on preliminary data. Unlike many grants that expect strong preliminary evidence, this award discourages it because heavy preliminary support can signal that the work is no longer truly exploratory. Applicants who already have substantial preliminary datasets are encouraged to pursue other funding mechanisms that are better aligned with later-stage development. If preliminary data appear in an application, they are expected to be limited to serendipitous or unexpected observations, or results that emerged incidentally from unrelated studies, rather than a cohesive dataset built specifically to de-risk the proposed project. This preference reinforces the program's goal: to enable investigators to test creative, early-stage ideas that have not yet been thoroughly validated.

The expected outcome is the generation of robust preliminary data by the end of the project, not the delivery of a fully mature technology or a near-clinical solution. Successful projects should produce convincing early evidence that can serve as a launchpad for future melanoma-focused proposals and larger-scale studies. In practical terms, this award functions as a catalyst for first-in-kind experiments that, if promising, can justify and shape subsequent, more definitive research efforts.

Administratively, the opportunity is listed as a discretionary funding program under Funding Opportunity Number HT9425 23 MRP IA, with funding instruments that may include either grants or cooperative agreements. The CFDA listing is 12.420, and eligibility is described as unrestricted, meaning a wide range of applicant organizations may apply, subject to any additional constraints stated in the full eligibility section of the solicitation. The posting indicates an expected 15 awards. The opportunity was created on May 18, 2023, with an original closing date of September 22, 2023. The notice shows an award ceiling of 0, which typically indicates that applicants must rely on the full announcement for the actual maximum allowable budget or that the ceiling is not expressed in that specific summary field, so the detailed solicitation is the authoritative source for budget limits and related rules.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "FY23 DoD Melanoma Idea Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 18, 2023.
• Applicants must submit their applications by Sep 22, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 15 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 MRP IA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: